We are live on
!
Find out more
EFM
E Fund Management Portfolio holdings
AUM
$3.37B
This Fund
S&P 500
This Quarter
Est. Return
+11.07%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.1B
AUM Growth
-$1.95B
(-64%)
Cap. Flow
-$2.01B
Cap. Flow
% of AUM
-182.11%
Top 10 Holdings %
Top 10 Hldgs %
55.43%
Holding
359
New
34
Increased
188
Reduced
93
Closed
36
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
STAAR Surgical
STAA
|
+$38.7M |
| 2 |
Sea Limited
SE
|
+$29.1M |
| 3 |
Mercado Libre
MELI
|
+$27M |
| 4 |
Meta Platforms (Facebook)
META
|
+$19.3M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$17.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alibaba
BABA
|
+$1.32B |
| 2 |
JD.com
JD
|
+$301M |
| 3 |
Baidu
BIDU
|
+$279M |
| 4 |
NetEase
NTES
|
+$202M |
| 5 |
Trip.com Group
TCOM
|
+$77.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 35.58% |
| 2 | Technology | 17.59% |
| 3 | Communication Services | 16.9% |
| 4 | Healthcare | 11.23% |
| 5 | Real Estate | 6.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
301
Atara Biotherapeutics
ATRA
$71.2M
| $200K | 0.02% |
1,025
+248
| +32% | +$40.5K |
|
302
Kura Oncology
KURA
$922M
| $194K | 0.02% |
+10,573
| New | +$152K |
|
303
Anavex Life Sciences
AVXL
$222M
| $193K | 0.02% |
19,244
+777
| +4% | +$7.36K |
|
304
uniQure
QURE
$2.68B
| $193K | 0.02% |
+10,364
| New | +$165K |
|
305
Coherus Oncology
CHRS
$217M
| $188K | 0.02% |
25,990
+12,504
| +93% | +$109K |
|
|
KYNB
306
Kyntra Bio
KYNB
$28.5M
| $184K | 0.02% |
698
+142
| +26% | +$36.3K |
|
307
Hewlett Packard
HPE
$63.2B
| $181K | 0.02% |
13,665
-125
| -0.9% | -$1.9K |
|
308
MannKind Corp
MNKD
$1.28B
| $177K | 0.02% |
46,376
+2,887
| +7% | +$10.6K |
|
309
Alector
ALEC
$164M
| $166K | 0.02% |
16,372
+4,938
| +43% | +$49.3K |
|
|
CPRX
310
DELISTED
Catalyst Pharmaceutical
CPRX
| $150K | 0.01% |
21,335
+9,721
| +84% | +$71.3K |
|
|
MYOV
311
DELISTED
Myovant Sciences Ltd.
MYOV
| $150K | 0.01% |
12,091
-1,510
| -11% | -$16.7K |
|
|
RDUS
312
DELISTED
Radius Health, Inc.
RDUS
| $142K | 0.01% |
13,662
+924
| +7% | +$6.87K |
|
313
Rigel Pharmaceuticals
RIGL
$680M
| $141K | 0.01% |
12,482
+10,735
| +614% | +$216K |
|
314
Gossamer Bio
GOSS
$66.5M
| $137K | 0.01% |
+16,419
| New | +$127K |
|
|
SGMO
315
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $131K | 0.01% |
31,592
+8,491
| +37% | +$36.7K |
|
316
Organogenesis Holdings
ORGO
$308M
| $126K | 0.01% |
25,808
+14,028
| +119% | +$86.3K |
|
317
Norwegian Cruise Line
NCLH
$8.89B
| $118K | 0.01% |
+10,598
| New | +$178K |
|
318
Viatris
VTRS
$20.1B
| $117K | 0.01% |
11,183
-1,905
| -15% | -$20.9K |
|
|
EQRX
319
DELISTED
EQRx, Inc. Common Stock
EQRX
| $103K | 0.01% |
+21,875
| New | +$98.6K |
|
320
Praxis Precision Medicines
PRAX
$9.07B
| $64K | 0.01% |
+1,738
| New | +$185K |
|
321
Geron
GERN
$911M
| $60K | 0.01% |
38,992
+7,305
| +23% | +$10.3K |
|
322
MiMedx Group
MDXG
$626M
| $42K | ﹤0.01% |
11,994
+1,321
| +12% | +$5.17K |
|
|
ADAG
323
Adagene
ADAG
$211M
| $39K | ﹤0.01% |
19,310
| – | – |
|
324
Akebia Therapeutics
AKBA
$327M
| – | – |
-35,250
| Closed | -$25K |
|
325
American Express
AXP
$223B
| – | – |
-1,224
| Closed | -$229K |
|
Similar funds
VFCM
DFO
DIA
5NCM
TAM
CS
OAM
QCG
E Fund Management's Q2 2022 Portfolio in Review
As of Q2 2022, E Fund Management held 359 positions worth $1.1B, down 64% from $3.06B the previous quarter. Its ten largest holdings account for 55% of the portfolio.
E Fund Management withdrew a net $2.01B in Q2 2022, closing 36 positions and reducing 93 holdings. Its most notable exit was Alibaba, an estimated $1.32B position sold in full.
By sector, the portfolio is most concentrated in Consumer Discretionary at 36% of assets, down from 63% a quarter earlier, followed by Technology and Communication Services.
Against the trend, E Fund Management opened a new position in Sea Limited worth $22.9M.
- E Fund Management's largest Q2 2022 buy was Sea Limited: 342,000 shares worth $22.9M.
- E Fund Management added most to STAAR Surgical in Q2 2022, an estimated $38.7M increase.
- E Fund Management's biggest Q2 2022 reduction was JD.com, cutting an estimated $301M.
- E Fund Management fully exited Alibaba in Q2 2022, selling an estimated $1.32B.
- E Fund Management's ten largest holdings make up 55% of its $1.1B portfolio in Q2 2022.
- E Fund Management opened 34 new positions and closed 36 in Q2 2022.
- E Fund Management's portfolio value fell 64% quarter-over-quarter to $1.1B.
Based on E Fund Management's 13F filing for Q2 2022, filed 15 Aug 2022.